- Company
- Samsung Bioepis launches Stelara biosimilar Pyzchiva in US
- by Whang, byung-woo Feb 26, 2025 06:29am
- Samsung Bioepis announced on the 25th that its autoimmune disease treatment Pyzchiva (ustekinumab) has been launched in the US through its marketing partner Sandoz. Stelara’s biosimilar Pyzchiva is Janssen’s treatment for autoimmune diseases such as psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. Stelara’s a
- Company
- Celltrion’s Actemra biosimilar Avtozma receives EU approval
- by Chon, Seung-Hyun Feb 25, 2025 05:56am
- Celltrion announced on the 24th that it has received approval from the European Commission (EC) for the marketing authorization of its ‘Avtozma, a biosimilar of the autoimmune disease treatment 'Actemra (tocilizumab).’ The final approval was granted 2 months after receiving a recommendation for approval from the Committee for Medicinal P
- Company
- Antibody drugs, AI, and platform companies go public
- by Cha, Jihyun Feb 25, 2025 05:56am
- Domestic pharmaceutical, bio, and healthcare companies are floating IPOs one after another. Organoid Sciences is the first to challenge the market with its &160;gap technology. IntoCell plans to submit a securities report as early as next month. Companies in various fields, including biotech companies that develop new drugs, medical artificial
- Company
- Will overcoming CDRC review lead to reimb for 'Besremi'?
- by Eo, Yun-Ho Feb 25, 2025 05:56am
- Whether 'Besremi,' used to treat polycythemia vera, will be added to the National Health Insurance reimbursement list has gained attention. According to the industry sources, PharmaEssentia's Besremi (ropeginterferon alfa-2b) is awaiting to be considered for the Health Insurance Review and Assessment Service (HIRA)'s Drug Reimbursement Ev
- Company
- "Increasing role of Kisqali in breast cancer therapy"
- by Whang, byung-woo Feb 24, 2025 05:51am
- The introduction of CDK 4/6 inhibitors has changed the treatment paradigm for metastatic breast cancer, addressing previously unmet needs. The introduction of a new treatment option has been positively evaluated because the existing endocrine therapy, which is used as first-line treatment for HR+/HER2 advanced and metastatic breast cancer, ac
- Company
- Will Prevnar 20 be included in NIP in 1H 2025?
- by Whang, byung-woo Feb 24, 2025 05:51am
- Pfizer is seeking to release Pfizer’s new pneumococcal vaccine, Prevenar 20, in the first half of this year with its inclusion in the National Immunization Program (NIP) for children. According to industry sources, the Korea Disease Control and Prevention Agency and Pfizer have made progress in discussions on whether Prevnar20 should be
- Company
- Primary biliary cholangitis drug Iqirvo to land in Korea
- by Eo, Yun-Ho Feb 24, 2025 05:51am
- The new drug for primary biliary cholangitis Iqirvo may soon be launched in Korea. According to industry sources, Ipssen Korea is in the process of obtaining marketing authorization from the Ministry of Food and Drug Safety for Iqirvo (elafibranor), a dual peroxisome proliferator-activated receptor (PPAR) alpha/delta (PPAR α, δ) agonist
- Company
- Pricing negotiations for Vocabria+Rekambys combo complete
- by Eo, Yun-Ho Feb 24, 2025 05:51am
- The long-acting HIV drug Vocabria+Rekambys combination therapy is on the verge of being reimbursed in Korea, 2 years after its approval. According to industry sources, GSK Korea recently concluded drug price negotiations with the National Health Insurance Service for the combination therapy of the new HIV drugs Vocabria (cabotegravir) and
- Company
- Asthma drug Tezspire ready for launch
- by Whang, byung-woo Feb 21, 2025 05:56am
- Tezspire (tezepelumab), an anti-TSLP therapy for the treatment of severe asthma, is entering the market with its effectiveness regardless of biomarker status. Although the drug still faces reimbursement hurdle, clinical practices have high hopes. They expect that Tezspire's versatility can change the current treatment paradigm in which drug
- Company
- The aftermath of the prolonged medical care gap continues
- by Moon, sung-ho Feb 20, 2025 05:59am
- Global pharmaceutical companies are launching new blood cancer drugs in Korea one after another, but the situation on site is impeding their access. According to industry sources on the 17th, the the medical school admission expansion policy last year has led to a continued mass resignation of residents, which has disrupted the treatment of b
